<DOC>
	<DOCNO>NCT00983788</DOCNO>
	<brief_summary>The investigator propose evaluate effect bezafibrate metabolism exercise 22 adult patient affect carnitine palmitoyltransferase II ( CPTII ) very-long chain acyl-CoA-dehydrogenase ( VLCAD ) deficiencies . This study 9-month , randomize , double-blind , placebo-controlled crossover trial . The trial conduct two center : Institut de Myologie , Pitié-Salpêtrière Hospital France , Rigshospitalet , University Copenhagen , Denmark . The main criterion assess potential effect drug fat oxidation rate study moderate workload cycle ergometer , infusion stable isotope ( palmitate glucose tracer ) .</brief_summary>
	<brief_title>Effect Bezafibrate Muscle Metabolism Patients With Fatty Acid Oxidation Defects</brief_title>
	<detailed_description>Background research aim : Carnitine palmitoyltransferase II ( CPTII ) very-long chain acyl-CoA-dehydrogenase ( VLCAD ) deficiencies two common inherit disorder mitochondrial fatty acid oxidation ( FAO ) adult , inherit autosomal recessive manner . Mitochondrial FAO play pivotal role maintain energy homeostasis situation fast , fever prolonged exercise require glucose spar major energy supply . In situation , number tissue skeletal muscle , heart , liver , favour fatty acid main source energy . Long-chain fatty acid ( LCFA ) , represent major part endogenous free fatty acid enter mitochondrial matrix compartment simple diffusion , transfer LCFA across mitochondrial membrane govern multienzymatic system name carnitine palmitoyltransferase ( CPT ) consist two enzyme : CPT I II . CPT I , key regulatory step LCFA oxidation , locate within out mitochondrial membrane , CPT II append inner face inner mitochondrial membrane . CPTs I II catalyze single reaction ( carnitine + acyl-CoA ⇔ acylcarnitine + CoA~SH ) forward reverse direction , respectively . VLCAD bound inner mitochondrial membrane , catalyse first step long-chain fatty acid β-oxidation spiral ( Izai et al. , 1992 ) . Various phenotype CPT II VLACD deficiency describe . Severe neonatal infantile clinical life-threatening symptom may occur hypoketotic hypoglycemia , liver failure , cardiomyopathy first month year life ( Demaugre et al , 1991 ; Bonnefont et al , 1996 ; Vianey-Saban et al . 1998 ; Andresen et al. , 1999 ) . Conversely , `` adult '' form diseases prevalent clinical expression restrict skeletal muscle . In latter form , onset often occur teenager young adult , mainly characterize recurrent episode rhabdomyolysis trigger prolonged exercise , fasting , cold fever ( DiMauro et al. , 1973 ; Vianey-Saban et al . 1998 ) . The major potential complication acute renal failure follow attack rhabdomyolysis . Studies fuel utilization subject CPT II VLCAD deficiency , stable isotope exercise , show vivo oxidation LCFA severely impair prolonged , low-intensity exercise . These finding indicate residual CPT II VLCAD activity sufficient maintain normal oxidation fat rest , fat oxidation rate increase basal level exercise ( Ørngreen et al. , 2004 ; 2005 ) . Current recommend treatment long-chain FAO disorder essentially rely dietary approach , restriction long-chain fat intake along medium-chain triglyceride supply ( MCT oil ) . A carbohydrate-rich diet also improve exercise tolerance CPT II-deficient patient , indicate lower perceived exertion increase duration exercise diet ( Ørngreen et al. , 2003 ) . More recently , remarkable improvement cardiac muscular symptom occur three child VLCAD deficiency , dietary supplementation seven-carbon medium chain fatty acid ( triheptanoïn ) . The mechanism underlie effect believe involve production C5 ketone body propionyl-CoA , allow replenishment pool catalytic intermediate citric acid cycle ( Roe et al. , 2002 ) . This promising approach still evaluation mark digestive side effect could restrict indication towards severe form FAO defect . Pharmacological approach mainly carnitine supplementation order provide carnitine convert potentially toxic long-chain acyl-CoAs acylcarnitines . However , role carnitine supplement FAO defect remain controversial unproven value due absence control trial . PPARα receptor identify potential target pharmacological therapy CPTII VLCAD deficiency . PPARα transcription factor , belong superfamily steroid-thyroid hormone receptor , able modify CPT2 VLCAD gene expression ( Lemberger et al , 1996 ) . Djouadi et al . establish administration control mice CPT I inhibitor ( etomoxir ) cause feedback induction PPARα target gene involve fatty acid oxidation medium-chain acyl-CoA dehydrogenase acyl-CoA oxidase gene ( Djouadi et al , 1998 ) . PPARα also show regulate constitutive expression CPT2 gene protein adult mouse heart liver mediate up-regulation CPT2 gene response fibrates mouse liver ( Aoyama et al , 1998 , Watanabe et al , 2000 ) . In human , `` fibrate '' class hypolipidaemic drug ( clofibrate , bezafibrate , gemfibrozil , etc… ) specific ligands PPARα interaction PPARα form molecular basis therapeutic effect drug ( Vamecq et al , 1999 ) . The research group Bastin J Djouadi F hypothesize hypolipidemic drug bezafibrate , act activator PPARα , might stimulate FAO CPT II VLCAD-deficient cell line . Bezafibrate treatment fibroblast four CPT II-deficient patient `` adult '' form disease show 1 ) increase amount CPT2 mRNA ( + 47 % + 66 % ) residual CPT II enzyme activity ( + 54 % + 135 % ) time- dose-dependant manner , 2 ) normalize 3H-palmitate 3H-myristate oxidation rate . Conversely , bezafibrate correct FAO two patient `` infantile '' form CPTII deficiency ( Djouadi et al , 2003 ) . Since clinical expression `` adult '' form CPT2 deficiency restrict skeletal muscle , effect fibrates test FAO muscle sample patient . After provided muscle sample patient `` adult '' form CPTII deficiency follow Institute Myology ( P. Laforêt , B. Eymard ) , show myoblasts biopsy exhibit 40 % decrease FAO compare control cell ( Djouadi et al , 2003 ) . Moreover , pretreatment CPTII-deficient myoblasts bezafibrate restore FAO normal level ( Bastin et al , 2003 ) . More recently , Djouadi et al . ( 2005 ) demonstrate addition bezafibrate culture medium induce dose-dependent ( 3-fold ) increase palmitate oxidation capacity fibroblasts patient myopathic form VLCAD deficiency , severely affected patient . This biological improvement relate drug-induced increase VLCAD mRNA ( + 44 + 150 % ) , protein ( 1.5-2-fold ) residual enzyme activity ( 7.7-fold ) cell patient . Bezafibrate also diminish production long-chain acyl-carnitines 90 % cell harbor moderate VLCAD deficiency . The group also investigate response bezafibrate function genotype 33 VLCAD-deficient fibroblast represent 45 different mutation . Treatment bezafibrate result marked increase FAO capacity , often leading restoration normal value , 21 genotype mainly correspond patient myopathic phenotype ( Gobin-Limballe et al. , 2007 ) . Situation research area result investigator area The data provide first evidence possible pharmacological effect PPAR agonists FAO defect human . In last two year , pilot clinical trial assess potential beneficial effect bezafibrate muscular form CPT II deficiency perform collaboration Pitié-Salpêtrière Necker hospital ( appel d'offre AFM 2004 ) . Six adult patient CPT II-deficiency receive daily 400 mg dose bezafibrate 6 month . Clinical tolerance treatment excellent , muscular symptom improve 5/6 patient decrease myalgia intensity duration . In vitro analysis carry lymphocyte skeletal muscle , sample prior to- end study . LCFAO isolate muscle mitochondrion strongly induce 6/6 patient , effect show result drug-induced up-regulation CPT2 mRNA protein level ( Djouadi et al. , 2007 ) . However major endpoint study mainly biochemical analysis , able clearly demonstrate decrease frequency rhabdomyolysis attack , neither improvement vivo muscle metabolism . We propose evaluate effect bezafibrate metabolism exercise adult patient affect CPT II VLCAD deficiency . This study 11-month , randomize double blind , placebo-controlled crossover trial . The trial conduct two center : Institut de Myologie , Pitié-Salpêtrière Hospital France Neuromuscular Research Unit , Rigshospitalet , University Copenhagen , Denmark . Since exercise test cycle ergometer stable isotope infusion probably reliable way ass vivo fat oxidation , technique utilized one two major outcome study , main criterion assess potential effect drug fat oxidation rate moderate workload cycle ergometer . The two primary outcome asses potential effect Bezafibrate : • Fat oxidation heart rate generate physical activity cycle ergometer constant workload . We expect fat oxidation patient increase factor 1.7 . Secondary outcome : - Enzyme activity leucocytes - Acylcarnitine profile - Accelerometer - Borg score ( perceived exertion ) - Number episodes myoglobinuria - Daily muscle pain score ( VAS ) - Daily diary energy utilization ( Bouchards questionnaire ) Material method : Subjects This study 9-month , randomize , double blind , placebo-controlled , crossover trial . Based calculation strength section statistic 22 patient , respectively 11 patient CPT II 11 patient VLCAD deficiency include study : The adult form CPTII VLCAD deficiency rare disease . Twenty-five patient CPTII deficiency 15 patient myopathic form VLCAD deficiency currently follow two group . In case ca n't include enough patient Denmark France , include patient collaborator Netherlands Sweden . All study conduct Rigshospitalet Pitié-Salpêtrière Hospital . Only regularly blood sample outsource hospital , result fax mail directly sponsor investigator . The study conduct two center : 1 . Neuromuskulær Forskningsenhed , Rigshospitalet , Danmark 2 . Institut de Myologie , Pitié-Salpêtrière Hospital , Frankrig In collaboration 3 . Copenhagen Region Pharmacy , Alice Rosendahl , Marielundvej 25 , Herlev , Denmark 4 . Copenhagen Muscle Research Center , Rigshospitalet , Blegdamsvej 9 , København Ø , Denmark 5 . GCP-unit , Bispebjerg hospital , Bispebjerg Bakke 23 , København NV , Denmark The study divide four period : - First period : 1 month observation period . - Second period : 3 month treatment either Bezafibrate placebo . - Third period : 2 month wash . - Fourth period : 3 month treatment either Bezafibrate placebo ( opposite drug second period ) . Patients fill daily score muscle pain ( VAS score ) energy utilization ( Bouchards questionnaire ) four period . First period : 1 . Prior randomize patient 1 month observation period . 2 . Creatin kinase measure regularly period define level muscle damage treatment . 3 . To determine workload 50 % maximal oxygen uptake ( VO2max ) experiment , subject complete maximal incremental cycle exercise test cycle ergometer end period . Second fourth period : 1 . Subjects instruct follow standardized carbohydrate rich diet three day prior experiment contain 65 % carbohydrate , 15 % protein 20 % fat . 2 . Fat oxidation study : After 3 month observation period subject meet lab 9.00 a.m. Two catheter insert arm vein , one cubital vein stable isotope infusion one distal cephalic vein blood sampling . The subject receive prim , constant rate infusion [ U-13C ] -palmitate ( 0.0026 mg kg-1 min-1 , prim 0.085 mg kg-1 NaH13CO3 bolus , NB ! non-radioactive non-dangerous tracer ) . Two hour start isotope infusion , subject cycle exhaustion maximum 60 min . workload 50-60 % VO2max previously determine . Heart rate level perceive exertion ( Borg Scale ) monitor every minute exercise . Blood expire gas isotope measurement collect 10 min interval rest exercise . Expired air collect 15 L Douglas bag , 10 ml air sample bags inject vacutainer tube analyse 13CO2 enrichment . Blood sample acyl carnitines collect 30 60 min . exercise exhaustion , three hour exercise . Enzyme activity CPT II VLCAD measure leucocyte . The above-described test execute treatment period . 3 . Patients randomize two group , receive either 3 x 200mg bezafibrate placebo second period vice versa fourth period . Patients health care personal blind treatment . The randomization carry GMP-certified regional pharmacy Copenhagen . 4 . On first trial day two period patient blood sample take analyse creatin kinase , cholestrol , triglyceride , lipoprotein , total long-chain fatty acid , total carnitine , acylcarnitines , bilirubin , creatinin , aspartate amino transferase ( ASAT ) , alanine amino transferase ( ALAT ) , γ glutamyl transferase alcalic phosfatase . 5 . To indicate activity level , patient carry accelerometer last fourteen day treatment period . Third period : 1 . Two month wash-out period . 2 . Measurements creatin kinase level every second week . Statistical analysis Strength calculation : Double blind , randomise crossover : ( z1-α/2 + Z1-β ) 2 * SD2 n ≥ _________________________ d2 Z1-α/2 = 1.96 ; Risk type 1 error ( α=0.05 ) Z1-β = 0.84 ; Risk type 2 error : ( 1-β ) = 80 % SD2 = 1.25 ; delta palmitate oxidation four patient CPT II deficiency = 1.26±1.12 ( Ørngreen et al , 2005 ) d2 = 0.87 ; ( MIREDIF ) increase palmitate oxidation exercise level patient double CPT2 gene mutation level single CPT2 gene mutation subject . ( Ørngreen et al , 2005 ) . ( 1.96 + 0.84 ) 2 * 1.25 n ≥ _________________________ = 11 0.87 The strength calculation base former study fat oxidation patient CPT II deficiency . Ørngreen et al 2005 In study describe fat oxidation patient carrier respectively two one CPT2 gene mutation compare fat oxidation healthy control . The expected effect bezafibrate fat oxidation CPT II patient expect difference mean value fat oxidation patient CPT II deficiency mean value fat oxidation heterozygous carrier one CPT2 gene mutation . The strength calculation indicate number 11 subject need include . The aim include 11 patient respectively group patient CPT II deficiency group patient VLCAD deficiency . If somehow turn include many patient . The two group pool one group . This do similarity two group symptom fat oxidation , one primary outcome , exercise.Ørngreen et al 2005 , Ørngreen et al 2004 Missing data : As long patient complete least one treatment period , result include data . Differences treatment individual assess paired Student 's t-test . A p value &lt; 0.05 ( two-tailed testing ) consider significant . Patients Inclusion criterion : 1 . Significant decrease CPT II VLCAD activity measure lymphocyte fibroblast , together genetic verification either CPT II deficiency VLCAD deficiency . 2 . Males females age 18-65 year . 3 . All fertile female negative pregnancy test use anti-conceptive study period . Exclusion criterion : 1 . Ingestion competitive drug , describe product resume bezafibrate . 2 . Competitive disorder , evaluate sponsor investigator 3 . Pregnancy lactation period fibrate therapy Safety parameter : - CK every week ± one week treatment period . - Hepatic enzyme ( AST , ALT , γGT , alkaline phosphate ) , bilirubine , creatinine , cholesterol , triglycerides treatment period , 1 month ± one week end treatment period . Blood sample take local hospital result fax sponsor investigator . - All patient inform contact one doctor involve case : 1 ) symptom disease 2 ) side effect treatment . Following step follow ensure compliance patient treatment period . - Patients contacted weekly mail telephone , ensure treatment follow symptoms disease side effect treatment . - In case one patient forget follow prescription drug , treatment period prolong evaluation sponsor investigator . Drugs : In study use fibrate Bezafibrate . For detailed information effect side effect , please see attach file product resume Bezafibrate . Randomizing un-blinding : All drug deliver blind randomize pharmacy . In occurrence life threaten unacceptable side effect treatment , patient un-blinded decision sponsor investigator . The randomization list keep secretary Malene Kronborg Have MD Tina Dysgaard Jeppesen Denmark . These two person available 24 hour day involve study otherwise .</detailed_description>
	<mesh_term>Lipid Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Bezafibrate</mesh_term>
	<criteria>CPT II VLCAD deficiency Competing disorder Liver kidney disease Allergy towards fibrates Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>CPT II</keyword>
	<keyword>VLCAD</keyword>
</DOC>